Search Results - "Koza, I"

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients by Smith, I.E., Pierga, J.-Y., Biganzoli, L., Cortés-Funes, H., Thomssen, C., Pivot, X., Fabi, A., Xu, B., Stroyakovskiy, D., Franke, F.A., Kaufman, B., Mainwaring, P., Pienkowski, T., De Valk, B., Kwong, A., González-Trujillo, J.L., Koza, I., Petrakova, K., Pereira, D., Pritchard, K.I.

“…First-line bevacizumab combined with chemotherapy significantly improves efficacy versus chemotherapy alone in human epidermal growth factor receptor 2…”
Get full text

Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study by Mego, M, Koncekova, R, Mikuskova, E, Drgona, L, Ebringer, L, Demitrovicova, L, Nemova, I, Trupl, J, Mardiak, J, Koza, I, Zajac, V

“…Febrile neutropenia (FN) remains a potentially life-threatening complication of anticancer chemotherapy. Bacterial translocation via intestinal mucosa is a…”
Get full text

Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study by Mardiak, J, Sálek, T, Sycová-Milá, Z, Obertová, J, Hlavatá, Z, Mego, M, Recková, M, Koza, I

“…The aim of this study was to determine efficacy and toxicity of TIP combination (paclitaxel, ifosfamid, cisplatin) as first salvage treatment in patients with…”
Get more information

Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study by Mardiak, J, Sálek, T, Sycová-Milá, Z, Obertová, J, Recková, M, Mego, M, Hlavatá, Z, Brozmanová, K, Risnyovzská, Z, Svetlovská, D, Koza, I

“…First line treatment of patients pts with poor-prognosis GCT, using BEP, is unsatisfactory. T-BEP (paclitaxel followed by BEP) demonstrated promising efficacy…”
Get more information

Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer by Sufliarsky, J, Chovanec, J, Svetlovska, D, Minarik, T, Packan, T, Kroslakova, D, Lalabova, R, Helpianska, L, Horvathova, D, Sevcik, L, Spacek, J, Laluha, A, Tkacova, V, Malec, V, Rakicka, G, Magdin, D, Jancokova, I, Dorr, A, Stresko, M, Habetinek, V, Koza, I

“…Despite progress in primary treatment of patients with advanced ovarian cancer, the majority develop recurrence of the disease. A platinum salt treatment,…”
Get more information

Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I by Mego, M, Ebringer, L, Drgona, L, Mardiak, J, Trupl, J, Greksak, R, Nemova, I, Oravcova, E, Zajac, V, Koza, I

“…Febrile neutropenia (FN) remains a potentially life-threatening complication of anticancer chemotherapy. Bacterial translocation via intestinal mucosa is a…”
Get more information

5017 Multinational study (n = 2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391 by Cortes-Funes, H, Pritchard, K.I, Biganzoli, L, Thomssen, C, Pierga, J, Koza, I, Kwong, A, Kellokumpu-Lehtinen, P, Chlistalla, A, Smith, I

Get full text

Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study by Mardiak, J, Sálek, T, Sycová-Milá, Z, Obertová, J, Hlavatá, Z, Mego, M, Recková, M, Koza, I

“…The aim of the study was to determine the efficacy and toxicity of gemcitabine, cisplatin and paclitaxel (GCP) combination as a first salvage treatment of…”
Get more information

3046 POSTER A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer by Ciuleanu, T.E, Scheithauer, W, Kurteva, G, Ocvirk, J, Koza, I, Papamichael, D, Wenczl, M, Brodowicz, T, Zielinski, C.C, Beslija, S

Get full text

Carboplatin and cyclophosphamide in the treatment of metastatic seminoma by Mardiak, J, Sálek, T, Sycova-Milá, Z, Sufliarsky, J, Baláz, M, Koza, I

“…Cisplatin-based chemotherapy is highly effective in advanced seminoma, but at the cost of a considerable toxicity. The response rate of carboplatin is…”
Get full text

Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors by Mardiak, J, Fuchsberger, P, Lakota, J, Sálek, T, Sycová-Milá, Z, Drahokoupilová, M, Baláz, M, Koza, I

“…Intermediate high dose VIP (etoposide, ifosfamide, cisplatin) achieved comparable efficacy and improved tolerance in comparison with high-dose chemotherapy…”
Get full text

Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX+C) or FOLFIRI + cetuximab (FF+C): The CECOG/CORE1.2.001 trial by Koza, I., Wrba, F., Vrbanec, D., Ocvirk, J., Ciuleanu, T. E., Beslija, S., Papamichael, D., Messinger, D., Zielinski, C. C., Brodowicz, T.

“…Abstract only 4055 Background: Previous retrospective analyses of KRAS mutation status from the randomized CECOG/CORE 1.2.001 phase II trial has shown that…”
Get full text

Sequential development of chronic lymphocytic leukemia in a patient with polycythemia vera by Koza, I, Babusíková, O

“…A patient with a seven-year history of polycythemia vera treated by repeated phlebotomies and intermittent busulfan administration developed gradually…”
Get full text

Determination of suramin in clinical samples using HPLC by BRANDSTETEROVA, E, CHOVANCOVA, V, KOZA, I, MARDIAK, J, HAL'KO, J

“…High-performance liquid chromatography (HPLC) was applied for the determination of suramin levels in serum samples from cancer patients treated with this drug…”
Get full text

Therapy of P388 leukemia with benzaldehyde by Balázová, E, Koza, I

“…Optimal schedules of benzaldehyde (50-100 mg kg-1 intraperitoneally) on day 1 or on several days after inoculation of 10(5) P388 leukemia cells to DBA 2J mice…”
Get full text

Perspectives of medical therapy of solid tumours by Koza, I

“…In the course of 55 years of its existence clinical chemotherapy succeeded in curing some types of leukaemia, aggressive lymphomas and some patients with some…”
Get more information

A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) by Ciuleanu, T. E., Kurteva, G., Ocvirk, J., Beslija, S., Koza, I., Papamichael, D., Vrbanec, D., Brodowicz, T., Scheithauer, W., Zielinski, C. C.

“…Abstract only…”
Get full text

Candidosis, aspergillosis and zygomycosis in an oncology department by Krcméry, Jr, V, Koza, I, Fuchsberger, P, Spánik, S, Trupl, J, Gyarfás, J, Sufliarsky, J, Agh, F, Horváth, A, Mardiak, J

“…The incidence, aetiology and treatment of fungal infections in a 60-bed department of clinical oncology over 2 years is reported. During the second year, after…”
Get more information

Netilmicin plus ceftriaxone versus amikacin plus ceftriaxone in the treatment of infections in granulocytopenic patients by Krcméry, Jr, V, Koza, I, Mardiak, J, Fuchsberger, P, Spánik, S, Trupl, J, Horníková, M, Kusenda, Z, Sufliarsky, J, Svec, J

“…For the treatment of febrile episodes in granulocytopenic cancer patients, a combination of bactericidal and intravenously administered broad spectrum agents…”
Get more information

Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients by Krcméry, Jr, V, Fuchsberger, P, Gocár, M, Salát, T, Bodnárová, J, Sobota, R, Koza, I, Svec, J

“…The nephrotoxicity of various combinations of antibiotics--aminoglycosides, cephalosporins, vancomycin, amphotericin B--in 171 oncologic patients is described…”
Get more information